Targeting EGFR and HER2 with 211At-Labeled Molecules: Unexpected and Expected Dose-Effect Relations in Cultured Tumor Cells

Publisher： Bentham Science Publishers

E-ISSN： 1874-4729|1|3|225-233

ISSN： 1874-4710

Source： Current Radiopharmaceuticals, Vol.1, Iss.3, 2008-09, pp. : 225-233

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer

By Hare Jennifer I.   Moase Elaine H.   Allen Theresa M.  

Journal of Drug Targeting, Vol. 21, Iss. 1, 2013-01 ,pp. : 87-96

Informa Healthcare

Access to resources Recommend Favorite

Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers

By Desai Monica Dandona   Saroya Bikramajit Singh   Lockhart Albert Craig  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 3, 2013-03 ,pp. : 341-356

Informa Healthcare

Access to resources Recommend Favorite

Insight into the Medicinal Chemistry of EGFR and HER-2 Inhibitors

By  

Current Medicinal Chemistry, Vol. 21, Iss. 11, 2014-04 ,pp. : 1336-1350

Bentham Science Publishers

Access to resources Recommend Favorite

Biodistribution and Tumor Targeting of Indium and Iodine-labeled Shiga Toxin B-Subunit

By  

Current Radiopharmaceuticals, Vol. 2, Iss. 3, 2009-07 ,pp. : 184-190

Bentham Science Publishers

Access to resources Recommend Favorite

Alcohol and false recognition: a dose-effect study

By Mintzer Miriam   Griffiths Roland  

Psychopharmacology, Vol. 159, Iss. 1, 2001-12 ,pp. : 51-57

Springer Publishing Company

Access to resources Recommend Favorite